PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.12%
Cash & equivalents declining -5.12% while Biotechnology shows -4.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-5.12%
Cash + STI yoy growth 1.25-1.5x the Biotechnology median of -4.32%. Mohnish Pabrai might see a strategic surplus if short-term returns make sense.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
820.83%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-4.22%
1.25-1.5x the Biotechnology median of -3.68%. Mohnish Pabrai would examine if this advantage is strategic or idle cash buildup.
-17.65%
PP&E growth below half of Biotechnology median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-47.54%
Below half the Biotechnology median of 0.00%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
≥ 1.5x the Biotechnology median of -2.58%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
46.70%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-26.38%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
126.45%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
265.71%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
63.25%
Above 1.5x Biotechnology median of 2.56%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Above 1.5x Biotechnology median of 0.77%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
0.5-0.75x Biotechnology median of -5.28%. Guy Spier is cautious about weaker retention vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.40%
≥ 1.5x Biotechnology median of -4.63%. Joel Greenblatt sees stronger equity growth vs. peers.
-4.84%
≥ 1.5x Biotechnology median of -2.60%. Joel Greenblatt sees more aggressive expansions than peers.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-26.37%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
5.01%
Near Biotechnology median 6.63%. Charlie Munger sees typical yoy changes in net debt among the sector.